Although AML is typically characterized by a low mutation burden, certain high-frequency driver mutations, such as FLT3-ITD and NPM1 mutations, can generate immunogenic peptides that act as tumor-specific antigens, triggering targeted immune responses (31, 32). This evidence concerns the gene FLT3 and neoplasm.